Central serous chorioretinopathy patient treated with Lutronic’s R:GEN laser in Korea

Lutronic Vision’s R:GEN retina treatment laser has been used to treat the first patient with central serous chorioretinopathy at Seoul National University Hospital, the company announced in a press release.
R:GEN received conditional new health technology assessment approval from Korea’s Ministry of Health and Welfare in July 2018, which allows for out-of-pocket medical treatment and clinical data collection to support final approval and determine reimbursement coverage, the release said.
“The conditional approval is mutually beneficial: Patients are able to access treatment

Full Story →